Adjuvant vaginal cuff brachytherapy serves as an established standard of care to prevent local vault recurrence in postoperative women diagnosed with high-intermediate risk endometrial cancer. Historically, radiation oncologists utilize radiographic simulation—via computed tomography or orthogonal radiographs—to verify cylinder applicator seating, assess vaginal mucosa contact, and evaluate organ-at-risk dosimetry. However, routine simulation demands additional equipment time, increases patient discomfort, and generates healthcare expenses. Recent clinical evidence now evaluates whether omitting routine imaging simulation impacts therapeutic efficacy.

Vaginal Cuff Brachytherapy Without Routine Simulation

In a large single-institution retrospective cohort study, investigators examined long-term oncologic outcomes in 255 women with high-intermediate risk endometrial cancer treated with vaginal cuff brachytherapy without radiographic simulation. Over a median follow-up period of 60.1 months, the researchers documented 11 vaginal recurrence events. Consequently, the 5-year cumulative incidence of vaginal recurrence was calculated at 3.6% (95% CI = 1.2–6.5%). These results provide reassuring real-world evidence supporting clinical cylinder placement techniques when managed by experienced multidisciplinary teams.

Comparative Outcomes with the PORTEC-4a Landmark Trial

To contextualize these findings, researchers benchmarked their outcomes against the standard brachytherapy arm of the landmark PORTEC-4a trial, which mandated strict imaging simulation and quality assurance for applicator positioning. In PORTEC-4a, the 5-year cumulative incidence of vaginal recurrence was 1.6% (95% CI = 0.00–3.32%). Statistical analysis indicated that the recurrence risk observed in the simulation-free cohort remained clinically comparable to the protocol-driven simulation cohort. Furthermore, subgroup analyses demonstrated that recurrence risks did not differ significantly across various clinical risk categories or specific applicator designs.

Dosimetric Considerations and Clinical Applicator Placement

Vaginal cylinder brachytherapy typically delivers highly localized surface or depth doses to the upper vaginal vault. When clinicians insert an appropriately sized cylinder that matches vaginal apical anatomy, adequate mucosal apposition is achieved reliably. While volumetric 3D image-guided brachytherapy provides detailed dosimetric verification for complex multi-channel or interstitial geometries, simple single-channel cylinder treatments follow standardized dose distributions. Therefore, experienced clinical insertion, careful cylinder diameter selection, and secure immobilization can achieve robust local coverage without mandatory per-fraction or baseline simulation scans.

Resource Optimization and Implications for Global Practice

Streamlining adjuvant radiation therapy pathways offers significant advantages for high-volume cancer centers, especially in resource-constrained environments across low- and middle-income countries. Eliminating routine simulation scans reduces scanner bottlenecks, minimizes radiation exposure from repeated planning imaging, and decreases overall treatment expenditure. Moreover, shorter procedure times substantially improve patient comfort and compliance during multi-fraction courses. Thus, this pragmatic treatment strategy expands treatment capacity without apparent compromises in local disease control.

Future Directions in Endometrial Cancer Risk Stratification

While the elimination of simulation provides workflow efficiency, patient selection remains critical. Modern gynecologic oncology increasingly incorporates molecular classification, including POLE mutations, mismatch repair deficiency, and p53 status, to guide adjuvant decisions. Patients harboring adverse biology or complex vaginal anatomy may still warrant customized volumetric imaging. Moving forward, prospective trials evaluating verification strategies will clarify the exact patient subsets that benefit from advanced image guidance versus those who can safely undergo streamlined clinical treatment.

Frequently Asked Questions (FAQs)

What is vaginal cuff brachytherapy?

Vaginal cuff brachytherapy is an internal radiation technique commonly delivered after hysterectomy for endometrial cancer. It utilizes an intra-vaginal applicator cylinder connected to a high-dose-rate radioactive source. This approach targets the upper vaginal apex, which represents the most frequent site of local disease relapse, while sparing adjacent pelvic normal tissues.

Why was imaging simulation traditionally required?

Simulation imaging with pelvic computed tomography or orthogonal radiographs was historically performed to verify cylinder contact with the vaginal vault apex. This process ensures proper applicator seating, detects apical air pockets, confirms geometric alignment, and calculates exact radiation dose constraints to adjacent sensitive organs, including the rectum and bladder.

Can omitting simulation compromise local cancer control?

Recent long-term clinical data demonstrate that omission of simulation does not compromise local cancer control in appropriately selected patients. With careful clinical sizing and proper physical insertion technique, 5-year vaginal recurrence rates remain below 4%, which is clinically comparable to recurrence rates observed in trial cohorts utilizing mandatory simulation verification.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional regarding individual clinical decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Eckelmann B et al. Simulation-free vaginal cuff brachytherapy for high-intermediate risk endometrial cancer. Brachytherapy. 2026 Aug 14. doi: undefined. PMID: 42601313.

2. van den Heerik ASVM, Horeweg N, Nout RA, et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: PORTEC-4a trial. Lancet Oncol. 2025;26(1):45-56.

3. Harkenrider MM, Block AM, Alektiar KM, et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy. 2017;16(1):95-108.